ModerateVitamin K antagonist anticoagulants×Imidazole derivatives (antiprotozoal / antibacterial)
Updated · Methodology
Mechanism
Acenocoumarol is a coumarin derivative and vitamin K antagonist: it reduces the activation of the vitamin K-dependent clotting factors II, VII, IX and X. Its effect is measured by the prothrombin time and the international normalised ratio (INR) (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). According to the Spanish metronidazole SmPCs, metronidazole can potentiate coumarin-type anticoagulants, acenocoumarol included, and raise the risk of bleeding because it slows their breakdown in the liver. The SmPCs do not name the enzyme involved (metronidazole SmPCs, AEMPS). The acenocoumarol SmPC names metronidazole among the imidazole derivatives that can potentiate acenocoumarol, and the generic SmPC lists it among antibiotics with the same effect (AEMPS). The US label states that metronidazole has been reported to potentiate warfarin and other oral coumarin anticoagulants and to prolong the prothrombin time (metronidazole prescribing information, US Food and Drug Administration, FDA). Infection and inflammation can reduce the protein binding of acenocoumarol, so strict medical supervision is needed during such periods (acenocoumarol SmPC, AEMPS).
Symptoms
The main risk is bleeding. The Spanish metronidazole SmPCs describe a higher risk of bleeding with coumarin-type anticoagulants, and the US label reports a prolonged prothrombin time (metronidazole summaries of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; metronidazole prescribing information, US Food and Drug Administration, FDA). Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an international normalised ratio (INR) above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal, uterine, nose and gum bleeding, vomiting blood and bleeding into joints. Fast heartbeat, low blood pressure, nausea, vomiting, diarrhoea and abdominal pain may follow (AEMPS).
Management
The combination is not contraindicated but needs frequent coagulation monitoring. During metronidazole treatment, check the prothrombin time frequently and adjust the anticoagulant dose (metronidazole summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US label asks for careful monitoring of the prothrombin time and the international normalised ratio (INR) (metronidazole prescribing information, US Food and Drug Administration, FDA). The acenocoumarol SmPCs ask for close and frequent coagulation checks, for example twice a week. This applies both when another drug is added and when it is stopped, including after the end of the antibiotic course (acenocoumarol SmPCs, AEMPS). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an INR below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. In severe bleeding, replace clotting factors with fresh whole blood, prothrombin complex concentrate or recombinant factor VIIa together with vitamin K1 (AEMPS). After bleeding, restart acenocoumarol once the INR is back in the target range (AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica Metronidazol Normon 250 mg comprimidos EFG (2026)– AEMPS, CIMA, nº registro 62223, revisión 01/2026, sección 4.5
- FDA: Flagyl (metronidazole) capsules – Prescribing Information (2026)– FDA, DailyMed SPL, Pfizer, Precautions (Drug Interactions)
- AEMPS: Ficha técnica: Metronidazol, Flagyl 250 mg comprimidos (nº registro 35034), sección 4.5 (2025)– AEMPS, CIMA, nº registro 35034, revisión 08/2025, secciones 4.3, 4.4, 4.5 y 4.8
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.5 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.5 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol Aurovitas 4 mg (nº registro 88315), sección 4.5 (2025)– AEMPS, CIMA, nº registro 88315 (Acenocumarol Aurovitas 4 mg comprimidos EFG; texto idéntico en 1 mg, nº 88278), revisión 07/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.9 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.9 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.9